« Back to news

The future's bright at Alderley Park

The future's bright at Alderley Park

Alderley parkManchester Science Parks (MSP) has outlined its vision for the future of AstraZeneca’s former R&D site in Cheshire, Alderley Park, which it acquired in March.

MSP said it wants to maintain top quality bioscience as the cornerstone of its commercial strategy at the 400-acre site.

The new state-of-the-art science hub will form an integral part of an ambitious global Life Science Strategy for the UK, as well as act as a driver for a single health science strategy for the North West region and beyond.

Speaking at the recent official launch event, Chris Oglesby, Bruntwood CEO and MSP Chairman, said: “Through our acquisition of Alderley Park, we have a unique opportunity to create a diverse innovative community of bioscience businesses which is internationally respected for the quality of its work and as a sustainable business model.

"With our partners and the community of exceptional scientists who choose to remain at the Park, we will build a flagship for a vibrant life sciences industry in the North of England.”

The vision for Alderley Park is supported by MSP’s public sector partners, which includes The University of Manchester.

Professor Dame Nancy Rothwell, President and Vice Chancellor, The University of Manchester, commented: “I am delighted to see the progress that has been made in ensuring the future of Alderley Park as a site of outstanding science. This has been achieved through excellent collaboration between the partners who are here today.”

Former owners of the site, AstraZeneca, will continue to have a long-term presence at Alderley Park, with more 700 employees retained on site, and will assist MSP in delivering its vision by supporting start-up and growing smaller life science businesses.

AstraZeneca has pledged a £5m contribution to the ‘Alderley Park Springboard Fund’ that will be used to support new businesses starting up at Alderley Park. MSP will also contribute £5m to the new fund.

Mene Pangalos, Executive Vice President Innovative Medicines and Early Development, AstraZeneca, stated: "As we handover ownership of Alderley Park, we can look back with pride on the important role the site has played in our success. We are delighted that our legacy of scientific innovation stretching back many decades will be built upon by Manchester Science Parks, helping ensure the UK remains a global leader in life sciences.” 

Share this: